CAMBRIDGE, Mass.--(BUSINESS WIRE)--Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial ...

As the importance and prevalence of oligonucleotide therapeutics continue to grow, so does the need for robust characterization methodologies throughout drug development and production. Given the ...

Nucleic-acid-based drugs have attracted significant funding and development by pharmaceutical and biotech companies in recent years, as researchers aim to harness their ability to halt the production ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration that immunogenicity assays may be necessary to measure immune responses to ...

This webinar will introduce novel chemically modified oligonucleotide tools that have the potential to treat multifactorial conditions (including cancer and drug resistance challenges) while ...

PepGen develops new therapies for genetic neuromuscular diseases using its Enhanced Delivery Oligonucleotide (EDO) platform. This technology is designed to improve the delivery of oligonucleotide ...